Pipeline

IN30758

IN30758 is a first in class ADC candidate targeting a specific integrin subtype that is highly expressed and abundant in various solid tumors, particularly in NSCLC and PDAC. This integrin subtype operates within the same signaling pathway as FAK, creating strong potential for synergy when combined with FAK inhibition. As a result, IN30758 represents a clinical advancement priority for indications with high integrin expression, with the potential to overcome acquired resistance to other targeted therapies, such as DXd-based ADCs.
As an ADC candidate, IN30758 exhibits several advantages over current treatment options. Its proprietary linker–topoisomerase inhibitor payload system is designed to enhance stability and efficacy while effectively countering drug resistance. The molecule has demonstrated robust preclinical efficacy across a range of cancer models, highlighting its broad utility. Furthermore, IN30758 has shown a wide therapeutic window and a favorable safety profile in non‑human primate studies, supporting its potential for safe and effective clinical translation.

IN30778

IN30778 is an innovative antibody-drug conjugate (ADC) that binds to a distinct tumor-associated antigen (TAA) with a unique expression profile across cancer types. While sharing a similar mechanism of action with IN30758, IN30778 targets a different subtype of integrin family. Its target antigen is highly and abundantly expressed in a range of solid tumors, particularly in colorectal and pancreatic cancers. Early research has demonstrated strong therapeutic potential, and preclinical studies support a favorable safety and tolerability profile alongside promising antitumor activity.
We have independently validated the potent anti-tumor efficacy of IN30778 across multiple models of various cancer types. Preclinical data indicate its therapeutic potential in colorectal, pancreatic, gastric, and prostate cancers.

Back